1. Short title This Act may be cited as the Advancing Safe Medications for Moms and Babies Act of 2023 . 2. Updating FDA regulations to remove pregnant women as a vulnerable research population (a) Purposes The purposes of this section are— (1) to facilitate compliance with applicable Federal regulations relating to the protection of pregnant women participating in research as subjects; and (2) to promote the inclusion of pregnant women in clinical research. (b) Harmonization For the purposes specified in subsection (a), the Secretary of Health and Human Services (in this Act referred to as the Secretary ) shall, to the extent practicable and consistent with other applicable statutes, issue such regulations as may be appropriate to harmonize the regulations of the Food and Drug Administration relating to the protection of human subjects, including parts 50 and 56 of title 21, Code of Federal Regulations, with the latest regulations of the Department of Health and Human Services relating to the inclusion of pregnant women as subjects in clinical research. (c) Deadline The Secretary of Health and Human Services shall finalize the regulations required by subsection (b) not later than 180 days after the date of enactment of this Act. 3. Clearinghouse of clinical trials and registries (a) In general The Secretary, acting through the Director of the National Institutes of Health, and in consultation with the Commissioner of Food and Drugs and the heads of other relevant Federal departments and agencies, shall establish and maintain a national clearinghouse of educational materials and current information on registries and clinical trials that enroll pregnant and lactating women in order to— (1) enable pregnant and lactating women, their families, and health care professionals to easily identify and enroll in registries and clinical trials; (2) educate pregnant and lactating women, their families, and health care professionals on the importance of enrolling in registries and clinical trials